Historical position

George Soros’s AbbVie (ABBV) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Soros Fund ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ1 2013Earliest verified positive filing snapshot
Latest statusHistorical positionBased on the latest supported relationship state
Peak shares1.54MHighest verified quarter-end share count
Quarters reported7Verified quarters with shares above zero
What happened?

Soros Fund Management first reported AbbVie in Q1 2013. The reported position was increased and reduced across later filings. Verified positive position history runs through Q3 2014. The current relationship status cannot be determined reliably from supported data.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q3 2014
Bought 924.8% more+1.39M shares · 1.54M shares reported after the change
Filing context

Quarter-end price $57.76 · Estimated holding basis $56.29

Q2 2014
Sold 57.1% of the position−200.00K shares · 150.00K shares remained
Filing context

Quarter-end price $56.44 · Estimated holding basis $42.66

Q1 2014
Sold 69.5% of the position−797.61K shares · 350.00K shares remained
Filing context

Quarter-end price $51.40 · Estimated holding basis $42.66

Q4 2013
Bought 14.8% more+147.61K shares · 1.15M shares reported after the change
Filing context

Quarter-end price $52.81 · Estimated holding basis $42.66

Q3 2013
Sold 0.9% of the position−8.75K shares · 1.00M shares remained
Filing context

Quarter-end price $44.73 · Estimated holding basis $41.16

Q2 2013
Bought 204.0% more+676.90K shares · 1.01M shares reported after the change
Filing context

Quarter-end price $41.34 · Estimated holding basis $41.16

Portfolio importance

How important was AbbVie in Soros Fund Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.9%Q3 2014
Last reported rank#34of 245 reported positions
Peak portfolio weight0.9%Q3 2014
Best historical rank#34Q3 2014
At peak importanceQ3 2014
ABBV
0.9%
Largest holding
4.9%
Cross-investor discovery

Who else owns AbbVie?

Also reported by 3 other tracked investors in their latest verified filings.

Joel GreenblattGotham Asset Management
ABBV0.1% of reported portfolio
Tom RussoGardner Russo & Quinn · formerly Gardner Russo & Gardner
ABBV0.0% of reported portfolio
Ray DalioBridgewater Associates, LP
ABBV0.0% of reported portfolio
Explore AbbVie across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$257.122026-09-11

Market context only; not an investor transaction price.

Latest filing quarter-end price$57.76Q3 2014

Derived from validated reported value and shares where supported.

Estimated holding basis$56.29Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View AbbVie stock page →

This tracker follows Soros Fund Management LLC’s Form 13F disclosures—not George Soros’s personal brokerage account. George Soros founded the firm; its current CEO and chief investment officer is Dawn Fitzpatrick. Form 13F does not reveal exact trade dates, execution prices or the purpose of an option position.